Silibinin: a toxicologist’s herbal medicine?

References

• Dekkers BGJ, Tan JL, Stam J, et al. Amanitin intoxication: Effect of therapies on clinical outcome – a review of 40 years of reported cases. Clin Toxicol. 2022;1–15.
   Web of Science ®Google Scholar
• Barceloux DG. Milk thistle, in Medical Toxicology of Natural Substances: Food, Fungi, Medicinal Herbs, Plants, and Venomous Animals. Hoboken NJ: Wiley and Sons. 2008; p. 553–557.
   Google Scholar
• Abenavoli L, Izzo AA, Milić N, et al. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacology, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202–2213.
   PubMed Web of Science ®Google Scholar
• Gillessen A, Schmidt HHJ. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301.
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs. 2001;15(7):465–489.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report on Silybum marianum. The Netherlands: European Medicines Agency; 2018.
   Google Scholar
• Xie Y, Zhang D, Zhang J, et al. Metabolism, transport and drug-drug interactions of silymarin. Molecules 2019;24(20):3693–3709.
   Web of Science ®Google Scholar
• Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules 2019;24(11):2155–2184.
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Dibildox-Martinez M, Sosa-Noguera J, et al. Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers. BMC Pharmacol Toxicol. 2019;20(1):5–11.
   PubMedGoogle Scholar
• Sornsuvit C, Hongwiset D, Yotsawimonwat S, et al. The bioavailability and pharmacokinetics of silymarin SMEDDS formulation study in healthy Thai volunteers. Evid Based Complement Alternat Med. 2018;2018:1507834. ID 1507834.
   PubMed Web of Science ®Google Scholar
• Faulstich H, Jahn W, Wieland T. Silybinin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung. 1980;30(3):452–454.
   PubMed Web of Science ®Google Scholar
• Magdalan J, Ostrowska A, Piotrowska A, et al. Failure of benzylpenicillin, N-acetylcysteine and silibinin to reduce alpha-amanitin hepatoxicity. In Vitro. 2009;23:393–400.
   Google Scholar
• Magdalan J, Ostrowska A, Piotrowska A, et al. Benzylpenicillin, acetylcysteine and silibinin as antidotes in human hepatocytes intoxicated with alpha-amanitin. Exp Toxicol Pathol. 2010;62(4):367–373.
   PubMedGoogle Scholar
• Floersheim GL, Eberhard M, Tschumi P, et al. Effects of penicillin and silymarin on liver enzymes and blood clotting factors in dogs given a boiled preparation of Amanita phalloides. Toxicol Appl Pharmacol. 1978;46(2):455–462.
   PubMed Web of Science ®Google Scholar
• Vogel G, Tuchweber B, Trost W, et al. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol. 1984;73(3):355–362.
   PubMed Web of Science ®Google Scholar
• Hruby K, Csomos G, Fuhrmann M, et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Human Toxicol. 1983;2:182–195.
   Google Scholar
• Ganzert M, Felgenhauer N, Schuster T, et al. Amanita poisoning: Comparison of silibinin with a combination of silibinin and penicillin. Dtsch Med Wochenschr. 2008;133(44):2261–2267.
   PubMed Web of Science ®Google Scholar
• Giannini L, Vannacci A, Missanelli A, et al. Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of 105 patients. Clin Toxicol (Phila). 2007;45(5):539–542.
   PubMed Web of Science ®Google Scholar
• Enjalbert F, Rapior S, Nouguier-Soulé J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002;40(6):715–757.
   PubMed Web of Science ®Google Scholar
• Mengs U, Pohl RT, Mitchell T. Legalon-Sil: the antidote of choice in patients with acute hepatoxicity from amanitin poisoning. Curr Pharm Biotechnol. 2012;13(10):1964–1970.
   PubMed Web of Science ®Google Scholar
• Mitchell ST, Olson KR. Intravenous silibinin for the management of amatoxin poisoning: First usage in an American cohort. (abstract). Clin Toxicol. 2008;46(5):396–397.
   Web of Science ®Google Scholar
• Gores KM, Hamieh TS, Schmidt GA. Survival following investigational treatment of Amanita mushroom poisoning: Thistle or shamrock? Chest 2014;146(4):e126–e129.
   PubMed Web of Science ®Google Scholar
• Mitchell T, Spyker D. Is intravenous silibinin a failed antidote for the fulminant hepatic failure treatment of amatoxin mushroom poisoning? Interim results of the North American clinical trial.(abstract). Clin Toxicol. 2017;55(7):696.
   Web of Science ®Google Scholar
• De Olano J, Wang JJ, Villeneuve Gosselin S, et al. Current fatality rate for suspected cyclopeptide mushroom poisoning in the United States. Clin Toxicol (Phila). 2021;59(1):24–27.
   PubMed Web of Science ®Google Scholar
• De Olano J, Su MK, Bianry R, et al. Is it Amanita phalloides? What is the value of a clinical diagnosis? (abstract). Clin Toxicol. 2018;56(10):944–945.
   Web of Science ®Google Scholar
• Letschert K, Faulstich H, Keller D, et al. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91(1):140–149.
   PubMed Web of Science ®Google Scholar
• MacKenzie CA, Austin E, Thompson M, et al. Cyclosporine as a novel treatment for amatoxin-containing mushroom poisoning: a case series. Toxicol Commun. 2022;6(1):23–27.
   Google Scholar
• Zuker-Herman R, Tong R, Wong A. Intravenous rifampicin use in the management of Amanita phalloides toxicity. Clin Toxicol (Phila). 2021;59(9):843–845.
   PubMed Web of Science ®Google Scholar